Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc

AIDS

Volumn 24, Issue 9, 2010, Pages 1382-1384

  Delobel, Pierre ^a,b,c   Raymond, Stéphanie ^a,b,c   Mavigner, Maud ^a   Cazabat, Michelle ^a,c   Alvarez, Muriel ^c   Marchou, Bruno ^b,c   Massip, Patrice ^b,c   Izopet, Jacques ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; ETRAVIRINE; GLYCOPROTEIN GP 120; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; BINDING AFFINITY; BINDING COMPETITION; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHENOTYPE; TRIAZOLES;

EID: 77952909975     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328338b7a6     Document Type: Letter

References (10)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
2. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al., MOTIVATE Study teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
3. Lewis M, Mori J, Simpson P, Whitcomb J, Li X, Robertson DL, Westby M. Changes in V3 loop sequences associated with failure of Maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials [poster #871]. 15th Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts, USA; 2008.
4. Mori J, Mosley M, Lewis M, Simpson P, Toma J, Huang W, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2 [abstract #10]. XVI International HIV Drug Resistance Workshop; Barbados; 2007.
5. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist mar-aviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
6. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
7. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-228.
8. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47:126-130.
9. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A,etal. Coreceptorusageofprimary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-7487.
10. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.